immunoassay semaglutide detection Sandwich-type homogeneous chemiluminescence based on nanoparticle toward of Aspergillus galactomannan antigen A fluorescence sandwich immunoassay for

doi: 10.2522/ptj.20130597 428 Torres-HardingSSorensonMJasonLMaherKFletcherMAReynoldsNet al

Case 2 A 27-year-old female with history of overweight (BMI of 37) currently on semaglutide for weight loss (0.5 mg/subcutaneous weekly injection for total of 16 weeks) presented to the oral medicine clinic with a chief complaint of xerostomia and dry lips for the past 12 weeks

In addition, studies have shown that most patients experience only mild side effects, and long-term health benefits outweigh them

Q What interferes with the assay

GLP-1 agonist medications have been on the market since 2005 with the release of exenatide (Byetta, AstraZeneca)